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Origins John Draize of the FDA published a procedure for
identifying contact allergens, using human volunteers. It became
known as the ‘‘repeated insult test’’ and was supposed to be an
improvement on the Schwartz-Peck test, also under FDA
sponsorship. Though Draize’s method did not have the force of
law, it came to be regarded as a quasi-legal regulation which put
a manufacturer of a topical drug at risk if the repeated insult test
had not been done.
To Dr. Kligman’s astonishment, he could not find any
published data which validated Draize’s test. He questioned
the number of subjects and exposures. Why 200 subjects?
Perhaps 100 would suffice? Why ten exposures, instead of 5, or
15 or 100? Subsequently, he learned there was a file in the FDA
archives, which on the basis of unpublished experience with
many topical agents, justified Draize’s specifications.
Dr. Kligman reasoned that the Draize test was ‘‘based not on
experimentation but on revelations originating in outer space.’’
Clinical experience had demonstrated that creams containing
penicillin were strongly allergenic, forcing them off the market.
Also, topical neomycin was known to have an appreciable risk of
sensitization. Certain topical bleaching agents, notably mono-
benzyl ether of hydroquinone, which were effective only
when applied daily for many months, could not continue to be
used because a substantial percentage of patients became
sensitized.
The stage was set for the important, and impertinent,
question. Would these well-known allergens be detected by
the Draize repeated insult test on 200 subjects? Dr. Kligman had
available a large population of prisoner volunteers on whom the
Draize test could be tested for its validity.
The result was stunningly negative. This ‘‘exalted, exagger-
ated, formidable procedure was incapable of recognizing
sensitizers.’’ It almost guaranteed that a formulation would pass
with flying colors. In a ‘‘kinky’’ sort of way, this lack of sensitivity
may actually have increased the reputation and commercial
usefulness of the test. After all, positive results hang a cloud of
allergenicity over a product which might be otherwise quite
useful. Benzoyl peroxide is an example of a useful drug which is
potentially a strong allergen. On the other hand, failure to detect
allergenic substances that are used daily can have disastrous
effects. For instance, the manufacturers of tetrachlorosalicyl-
anilide claim to have done three separate 200-subject Draize
tests in different facilities without discovering that this bacterio-
stat, incorporated in soaps, was a potent allergen. Had that been
known, the calamitous epidemic of photoallergy could have
been averted.
Development of the Maximization Test Dr. Kligman set out to
establish a simplified procedure which could consistently
identify contact sensitizers and which could also rate these
according to their sensitization potential, from weak to strong.
Dermatologists knew that sensitization was far more likely
when agents were applied to dermatitic, damaged skin. He took
advantage of sodium lauryl sulfate to induce a localized irritant
dermatitis. Being an anionic surfactant it had the further virtue of
making the horny layer barrier extremely permeable.
The upshot was that with 25 subjects, exposed to 5–48 h
patch tests, known allergens could be identified and ranked by
potency. The exposure conditions were chosen to use every
means to facilitate sensitization, so as to avoid false negative
results, hence the name, The Maximization Test.
World wide experience has demonstrated the specificity and
sensitivity of the test.
Comment It would be difficult to develop The Human
Maximization test in today’s political and legal climate.
Consequent to the publication of the test, Dr. Kligman was
vilified for his use of prisoner volunteers for his studies. As a
colleague of Dr. Kligman’s for 6 years, nothing is more absurd
to me than the accusation that he is a ‘‘racist’’ or ‘‘fascist.’’
Dr. Kligman throughout his career has demonstrated humanity
and generosity; his intellectual and financial support of medical
education and medical research has been exemplary.
The development of the maximization test should be
considered in historical context. Over the past 20 years, there
have been growing controls upon biomedical investigation. The
development of active institutional review committees for
human clinical research and animal rights committees for animal
related research is now a reality. Unquestionably, these review
procedures have heightened awareness of responsible behavior
by experimentalists involved in animal and human research.
However, there are times when one questions whether the
regulations serve the needs of patients, experimental animals, or
the bureaucracies themselves. There are recent major initiatives
to find alternatives to animal testing. This is a welcome step, but
the interdiction of responsible in vivo evaluation of topical
agents can be a serious blow to progress in cutaneous biology.
Albert Kligman’s Maximization test is a landmark in
cutaneous pharmacology. It has provided a unique method to
evaluate topical agents. It is also a very important reference point
in the complex, philosophic and sociologic evolution of
bio-medical investigation. One hopes that contributions such
as Dr. Kligman’s will be possible in the future [1,2].
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